27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
All test batteries exhibited some of the strengths of computerized cognitive testing: standardization of administration and stimulus presentation, accurate measures of response latencies, automated comparison in real time with an individual's prior performance as well as with age-related norms, and efficiencies of staffing and cost. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
We conclude that dementia and cognitive impairment are common among older adults with hip fractures. 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
One hundred and fifty probe-sets form an accurate classifier of young versus older muscle tissue and this healthy ageing RNA classifier performed consistently in independent cohorts of human muscle, skin and brain tissue (n = 594, AUC = 0.83-0.96) and thus represents a biomarker for biological age. 5 key findings →
Design: case-control study Participants: 594 Evidence: moderate
Full summary, score breakdown and related studies → Original source
A Systematic ReviewObstructive sleep apnoea, positive airway pressure treatment and postoperative delirium: protocol for a retrospective observational studyEvidence supporting the best clinical management of patients with multimorbidity and polypharmacy: a systematic guideline review and expert consensusDeprescribiendo para mejorar la salud de las personas o cuando deprescribir puede ser la mejor medicinaThe use of proton pump inhibitors among older adults with intellectual disability: A cross sectional observational studyNeed for Comprehensive Health Care Quality Measures for Older AdultsDevelopment and initial validation of prescribing quality indicators for patients with chronic kidney diseaseOlder patients' prescriptions screening in the community pharmacy: development of the Ghent Older People's Prescriptions community Pharmacy Screening (GheOP³S) toolA New Computer-Based Tool to Reduce Potentially Inappropriate Prescriptions in Hospitalized Geriatric PatientsThe Successful Aging After Elective Surgery Study: Cohort Description and Data Quality ProceduresRoutine deprescribing of chronic medications to combat polypharmacyAnnual Cognitive Assessment for Older Adults: Update for NursesThe impact of pharmaceutical care interventions for medication underuse in older people: a systematic review and meta-analysisAssessing appropriateness of osteoarthritis care using quality indicators: a systematic reviewCurrent Factors of Fragility and Delirium in Vascular SurgeryDrug-related problems identification in general internal medicine: The impact and role of the clinical pharmacist and pharmacologistPrescription of potentially inappropriate drugs for geriatric patients in long-term care: improvement through pharmacist's interventionChanging practice in dementia care in the community: developing and testing evidence-based interventions, from timely diagnosis to end of life (EVIDEM)High Prevalence of Poor Quality Drug Prescribing in Older Individuals: A Nationwide Report From the Italian Medicines Agency (AIFA)Delirium in elderly peopleDelphi consensus statement: Quality indicators for Inflammatory Bowel Disease Comprehensive Care UnitsPotentiality of STOPP/START criteria used in primary care to effectively change inappropriate prescribing in elderly patientsToo Much to ManageHip Fracture ManagementAppropriateness of Medication Prescribing Using the STOPP/START Criteria in Veterans Receiving Home-Based Primary CareActualización de la neumonía en el ancianoEstablishi 1 key finding →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
A biomarker panel was identified that included markers significantly increased (cortisol, pancreatic polypeptide, insulinlike growth factor binding protein 2, β(2) microglobulin, vascular cell adhesion molecule 1, carcinoembryonic antigen, matrix metalloprotein 2, CD40, macrophage inflammatory protein 1α, superoxide dismutase, and homocysteine) and decreased (apolipoprotein E, epidermal growth factor receptor, hemoglobin, calcium, zinc, interleukin 17, and albumin) in AD. 5 key findings →
Design: longitudinal study Participants: 207 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This 28-year study tracked depressive symptoms in over 10,000 people and found that depression appearing later in life (closer to a dementia diagnosis) was linked to higher dementia risk, but depression in midlife (decades before diagnosis) was not. 4 key findings →
Design: cohort Participants: 10,189 Evidence: moderate
Full summary, score breakdown and related studies → Original source
These findings indicate that AWV recipients had a timelier first MCI diagnosis than those who did not receive an AWV, but first ADRD diagnosis differed little. 5 key findings →
Design: cohort Participants: 549,516 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Biomarkers were measured in 431 Black and 583 White participants (mean age of 77 and 80 years and 17% and 21% of men, respectively), generating a balanced sample of 366:366. 3 key findings →
Design: cohort Participants: 1,014 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Low levels of vitamin D were associated with substantial cognitive decline in the elderly population studied over a 6-year period, which raises important new possibilities for treatment and prevention. 5 key findings →
Participants: 858 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
PSCI is common after stroke, especially in the first year, and ranges from mild to severe. 1 key finding →
Design: cohort study Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
People from the black ethnic group had a higher incidence of dementia diagnosis and those from the Asian ethnic group had lower incidence compared with the white ethnic group. 5 key findings →
Design: cohort study Participants: 2,511,681 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
These findings suggest that machine learning algorithms could accurately predict incident dementia within 2 years in patients receiving care at memory clinics using only 6 variables. 5 key findings →
Design: prospective cohort Participants: 307 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The impact of Parkinson's disease (PD) dementia is substantial and has major functional and socioeconomic consequences. 4 key findings →
Design: longitudinal study Participants: 486 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Epidemiological evidence regarding the association between atrial fibrillation (AF) onset age and risk of incident dementia remains unexplored. 4 key findings →
Design: cohort study Participants: 746 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Despite remarkable progress in the biomarker field in recent years, local validation of plasma biomarkers of Alzheimer’s disease (AD) and dementia is still lacking in Latin America. 5 key findings →
Design: cohort study Participants: 49 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This Position Paper evaluates the strengths and limitations of the International Working Group research diagnostic criteria and proposes advances to improve the diagnostic framework for Alzheimer's disease.
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Serum NFL is increased in ALS in comparison to other conditions and can serve as diagnostic and prognostic biomarker. 2 key findings →
Design: longitudinal study Participants: 124 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Longitudinal cognitive testing is essential for developing novel preventive interventions for dementia and Alzheimer's disease; however, the few available tools have significant practice effect and depend on an external evaluator. 4 key findings →
Design: longitudinal study Participants: 50 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Median survival was much lower than in screened populations. 3 key findings →
Design: cohort study Participants: 22 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Men, racial and ethnic minority individuals, older adults, and those with language barriers are at increased risk for undertreatment of depression. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
A MoCA cutoff score of 23, rather than the initially recommended score of 26, lowers the false positive rate and shows overall better diagnostic accuracy. 4 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
ABSTRACTObjective:To compare the accuracy of Mini-Mental State Examination (MMSE) and of the Montreal Cognitive Assessment (MoCA) in tracking mild cognitive impairment (MCI) and Alzheimer's Disease (AD). 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Plasma p-tau biomarkers had a greater diagnostic performance and larger effect sizes compared to t-tau and Aβ42/40 assays in detecting Aβ pathology. 5 key findings →
Design: cross-sectional Participants: 197 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Adherence was high (82.2%) and usability favorable. 4 key findings →
Participants: 1,815 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Altered functional connectivity precedes structural brain changes and symptoms in dementia. 5 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source
9 of the 1,743 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →